May 18, 2018 / 4:04 PM / in 5 months

BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts

May 18 (Reuters) - Rxi Pharmaceuticals Corp:

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS

* RXI PHARMACEUTICALS CORP - STUDY SUCCESSFULLY MEETS ITS PRIMARY EFFECTIVENESS OBJECTIVES AND ITS SECONDARY SAFETY AND TOLERABILITY OBJECTIVES

* RXI PHARMACEUTICALS CORP - STUDY RESULTS SHOW THAT SAMCYPRONE WAS SAFE AND WELL TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below